Dr. David Siegel, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Memorial Sloan Kettering Cancer Center

  Fellowship Hospital

• New York University-bellevue Medical Center

  Residency Hospital

• New York University Grossman School Of Medicine

  Medical School, 1986

• English

• French

• Italian

• Spanish

• KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma, 2021-06-18

• Associations Between Amplification (1q) and Prior Cancer in a Real-World De Novo Myeloma Cohort, 2021-01-04

• Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model, 2016-08-01

• IgA Monoclonal Gammopathy of Undetermined Significance and Complication ofStreptococcus mitisBacteremia, 2020-10-10

• Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment, 2020-05-06

• Patient-reported outcomes following autologous stem cell transplant for patients with multiple myeloma, 2021-06-27

• Phase Ib Dose-escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-dose Dexamethasone in Relapsed or Progressive Multiple Myeloma, 2013-02-27

• Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma, 2016-06-30

• I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients, 2022-09-23

• Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial, 2023-08-17

• Initial genome sequencing and analysis of multiple myeloma, 2011-03-24

• An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib, 2012-07-30

• Elotuzumab for the treatment of multiple myeloma, 2016-07-15

• Ex VivoMaintenance of Primary Human Multiple Myeloma Cells through the Optimization of the Osteoblastic Niche, 2015-05-14

• Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma, 2019-07-24

• Inhibition of NF-?B DNA binding suppresses myeloma growth via intracellular redox and tumor microenvironment modulation, 2022-12-02

• Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis, 2020-03-09